Related Experiment Video
Updated: Sep 6, 2025
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Current landscape of preclinical models of diabetic cardiomyopathy
Darnel Prakoso1, Miles J De Blasio2, Mitchel Tate1
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
Insights
Diabetic cardiomyopathy (DC) causes heart failure in diabetic patients, but effective treatments are lacking. This review examines preclinical models to understand DC mechanisms and guide new therapy development.
Area of Science:
- Cardiology
- Endocrinology
- Translational Medicine
Background:
- Diabetes mellitus significantly increases the risk of heart failure.
- Diabetic cardiomyopathy (DC) involves cardiac abnormalities preceding heart failure.
- Current treatments for diabetic heart failure are limited, representing a critical unmet medical need.
Purpose of the Study:
- To review and analyze existing preclinical models of diabetic cardiomyopathy (DC).
- To evaluate the strengths and weaknesses of various DC models in mimicking human disease features.
- To provide resources for improving preclinical research and facilitating translation to clinical applications.
Main Methods:
- Comprehensive literature review of genetic, pharmacologically induced, and diet-induced preclinical models of DC.
- Analysis of model alignment with human DC characteristics.
- Identification of tools and resources for future research.
Main Results:
- Preclinical models are crucial for elucidating the mechanisms underlying diabetes-induced heart failure.
- Different models (genetic, pharmacological, dietary) offer unique advantages and limitations.
- A critical need exists for models that accurately reflect human DC pathology.
Conclusions:
- Understanding DC mechanisms through preclinical models is essential for developing targeted therapies.
- Careful selection and application of appropriate preclinical models are vital for successful translation.
- This review offers guidance for optimizing preclinical research to address the unmet need in diabetic heart failure treatment.
Abstract:
Patients with diabetes have an increased risk of developing heart failure, preceded by (often asymptomatic) cardiac abnormalities, collectively called diabetic cardiomyopathy (DC). Diabetic heart failure lacks effective treatment, remaining an urgent, unmet clinical need. Although structural and functional characteristics of the diabetic human heart are well defined, clinical studies lack the ability to pinpoint the specific mechanisms responsible for DC. Preclinical animal models represent a vital component for understanding disease aetiology, which is essential for the discovery of new targeted treatments for diabetes-induced heart failure. In this review, we describe the current landscape of preclinical DC models (genetic, pharmacologically induced, and diet-induced models), highlighting their strengths and weaknesses and alignment to features of the human disease. Finally, we provide tools, resources, and recommendations to assist future preclinical translation addressing this knowledge gap.
More Related Videos
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025